Abstract:526 Background: The impact of COVID-19 on cancer patients may be attributed not only to its direct effects on the immune system but also to delays in diagnosis and treatment. Data on the effects of COVID-19 on pancreatic ductal adenocarcinoma (PDAC) patients are scarce. Therefore, we set out to determine the impact of the pandemic on diagnosis and treatment initiation. We hypothesized that time from diagnosis to treatment would be increased in the COVID era compared to the pre-COVID era. Methods: We conducted an IRB-approved retrospective chart review of 488 patients diagnosed with PDAC from March 2019 to September 2020 at two academic medical centers. Patients were divided into two groups, based on the date of initial pathologic diagnosis. We defined the pre-COVID era as March 2019 to March 2020, the 12-month time period before California's statewide lockdown. The COVID era was defined as the 6 months following the lockdown, March 2020 to September 2020. Demographics, clinical stage, and treatment type were recorded. In addition, initial clinical encounter date, pathologic diagnosis date, and initial treatment date were also collected. All data were gathered at two large-scale academic institutions. Descriptive statistics were used in the analysis. Results: There were 333 patients diagnosed during the pre-COVID era and 155 patients during the COVID era. While race/ethnicity and age at diagnosis were statistically similar for both groups, females made up a significantly larger proportion of COVID era patients than pre-COVID era patients ( p = 0.02). There was no significant difference in clinical stage at diagnosis between the two groups ( p = 0.84). In the pre-COVID era, 19.5% of cases were resectable, 11.1% borderline resectable, 20.1% locally advanced, and 31.8% metastatic. In the COVID era, 17.4% of patients were resectable, 11% borderline resectable, 23.9% locally advanced, and 32.9% metastatic. Median time from pathologic diagnosis to initiation of treatment was 32 days for the pre-COVID era patients and 28 days for the COVID era patients ( p = 0.38). Initial treatment type was also similar between the two groups ( p = 0.29). Conclusions: Fortunately, our data indicate that the COVID-19 pandemic has not significantly prevented PDAC patients from seeking care. Additionally, it does not appear that COVID-19 has delayed treatment initiation or changed initial treatment type. We believe that the successful adoption of telemedicine and other safety protocols have allowed patients with PDAC to continue receiving appropriate care during the pandemic. Impact of California COVID-19 lockdown on diagnosis and median time to treatment (days). Pre-COVID Era (Days, 95% CI) COVID Era (Days, 95% CI) p -value Time from symptom onset to clinical encounter 21 (14-31) 21 (15-31) 0.65 Time from clinical encounter to diagnosis 11 (9-13) 13 (10-17) 0.15 Time from diagnosis to treatment 32 (26-36) 28 (25-32) 0.38

Impact of COVID-19 on the time to counseling and treatment of prostate cancer

Impact of SARS-CoV-2-Pandemic on diagnosis of prostate cancer

Management of prostate cancer patients during COVID-19 pandemic

Impact of the coronavirus disease pandemic on robot‐assisted radical prostatectomy and urologists' treatment behaviors: A single tertiary center retrospective study

Post-Pandemic Aftermath: A Two-Year Follow-Up of the Effect of COVID-19 on Oncological Outcomes after Radical Prostatectomy for Prostate Cancer

The Impact of the Pandemic on the Quality of Colorectal and Anal Cancer Care, and 2-Year Clinical Outcomes

Impacts of the COVID-19 pandemic on the breast cancer control pathway in Ireland

Psychosocial distress after radical prostatectomy, radical cystectomy, or (partial) nephrectomy - a comprehensive analysis of 4,290 German cancer patients during the COVID-19 pandemic

Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial

A multi-institutional study of the impact of the COVID-19 pandemic on pancreatic cancer diagnosis and management.

The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy

The Incidence of Extreme Serum Prostate Specific Antigen Levels During the COVID-19 Pandemic

Crosstalk between COVID-19 and prostate cancer

The Impact of the COVID-19 Pandemic on Time to Treatment in Surgical Oncology: A National Registry Study in the Netherlands

Influence of the COVID-19 Pandemic on Patients with Rectal Cancer

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Retrospective Impact of COVID-19 Pandemic on Primary Breast Cancer Care

Impact of the COVID-19 pandemic on colorectal cancer stage at presentation.

Impact of the COVID-19 Outbreak—Delayed Referral of Colorectal and Lung Cancer in Primary Care: A National Retrospective Cohort Study

IMPACT OF THE COVID-19 PANDEMIC ON THE EMERGENCY SURGICAL TREATMENT OF COLORECTAL CANCER

Impact of the Early Phase of the COVID-19 Pandemic on the Quality of Care for Colorectal and Anal Cancers at Comprehensive Cancer Centers on Two Continents